Abstract
Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8%) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88%) of the eight patients with neoplastic lesions, but only in 15 (15%) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.
| Original language | English |
|---|---|
| Pages (from-to) | 471-481 |
| Number of pages | 11 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 22 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sep 1 2005 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Long-term follow-up in atrophic body gastritis patients : Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. / Lahner, E.; Bordi, C.; Cattaruzza, M. S.; Iannoni, C.; Milione, M.; Delle Fave, G.; Annibale, B.
In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 5, 01.09.2005, p. 471-481.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term follow-up in atrophic body gastritis patients
T2 - Atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection
AU - Lahner, E.
AU - Bordi, C.
AU - Cattaruzza, M. S.
AU - Iannoni, C.
AU - Milione, M.
AU - Delle Fave, G.
AU - Annibale, B.
PY - 2005/9/1
Y1 - 2005/9/1
N2 - Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8%) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88%) of the eight patients with neoplastic lesions, but only in 15 (15%) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.
AB - Background: Long-term outcome of atrophic body gastritis has not yet been defined. Aim: To investigate at long-term follow-up the behaviour of atrophy and intestinal metaplasia and the occurrence of neoplastic lesions in atrophic body gastritis patients. Methods: Overall 106 atrophic body gastritis patients with ≥ 4-year follow-up were studied; 38 were Helicobacter pylori-positive at histology + serology and cured of infection (group A), 36 were positive at serology and not treated (group B) and 32 were H. pylori-negative (group C). Patients underwent gastroscopy with antral (n = 3) and body (n = 3) biopsies for histology accord-ing to the Sydney System. Results: At 6.7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H. pylori status. Antral atrophy was significantly increased at follow-up only in group C, whereas antral intestinal metaplasia was unchanged in all three groups. During follow-up eight (8%) patients developed neoplastic lesions (one adenocarcinoma, one adenoma with low-grade dysplasia and six low-grade dysplasia without endoscopic lesions). Antral atrophic gastritis was present at baseline in all but one (88%) of the eight patients with neoplastic lesions, but only in 15 (15%) of the 98 patients without (P <0.0001, RR = 26.7). Conclusions: Atrophy and intestinal metaplasia persist at 6.7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.
UR - http://www.scopus.com/inward/record.url?scp=24344488684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24344488684&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2005.02582.x
DO - 10.1111/j.1365-2036.2005.02582.x
M3 - Article
VL - 22
SP - 471
EP - 481
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 5
ER -